Plasmodium falciparum Nicotinamidase as A Novel Antimalarial Target

Inhibition of Plasmodium falciparum nicotinamidase could represent a potential antimalarial since parasites require nicotinic acid to successfully recycle nicotinamide to NAD(+), and importantly, humans lack this biosynthetic enzyme. Recently, mechanism-based inhibitors of nicotinamidase have been discovered. The most potent compound inhibits both recombinant P. falciparum nicotinamidase and parasites replication in infected human red blood cells (RBCs). These studies provide evidence for the importance of nicotinamide salvage through nicotinamidase as a central master player of NAD(+) homeostasis in P. falciparum.

Automated summary

Inhibition of nicotinamidase in Plasmodium falciparum could potentially lead to the development of new antimalarial drugs. Studies have shown that a recently discovered compound is able to inhibit both the enzyme activity and replication of the parasite in infected human red blood cells. This suggests that nicotinamide salvage through nicotinamidase plays a crucial role in maintaining NAD(+) homeostasis in P. falciparum.